Goldman Sachs Upgrades Vertex Pharmaceuticals To Buy
Analysts at Goldman Sachs upgraded Vertex Pharmaceuticals (NASDAQ: VRTX) from Neutral to Buy.
The target price for Vertex Pharmaceuticals has been raised from $109 to $131.
Vertex Pharma shares have gained 16.00% over the past 52 weeks, while the S&P 500 index has surged 20.10% in the same period.
Vertex Pharmaceuticals' shares rose 0.22% to $95.25 in pre-market trading.
Latest Ratings for VRTX
|Dec 2016||Oppenheimer||Initiates Coverage On||Perform|
|Nov 2016||Janney Capital||Initiates Coverage On||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.